Elan has reported third quarter revenues of $306.6m for the three months to the end of September.
This is a rise of 10% on the $279.4m the same time last year.
But its net losses from continuing operations for the third quarter came to $216.2m compared to net income from continuing operations of $3.5m for the third quarter of 2011.
Elan said this was due to restructuring charges after the announcement of the separation of the Neotope business and the ending of Elan's early stage research activities.
It also had an impairment charge of $117.3m after the decision by Johnson & Johnson to end the development of a drug to treat mild to moderate Alzheimer's disease.
The company said that sales of its multiple sclerosis drug Tysabri grew by 3% to $403.8m in the third quarter from $392.6m the same time last year. This reflects a 17% growth in US net sales of the drug, which was offset by a drop of 11% in sales in the rest of the world due to currency movements.
The number of patients worldwide on Tysabri increased by 13% to about 71,100 at the end of September, up from 63,200 at the end of September 2011.
Elan said it has started a study in August of a molecule called ELND005 as a treatment for bipolar disorder.
''As the business transitions post the intended spin-off of Neotope, we will maintain our absolute focus on the current business by enabling growth of Tysabri in terms of adding net new patients globally, appropriately advancing the ELND005 molecule, and selectively exploring opportunities that would add to our value proposition in a balanced and thoughtful manner,'' commented Elan's chief executive Kelly Martin.
The company repeated its full year guidance of adjusted EBITDA of over $200m.
